Navigation Links
Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later

e;">

pressoffice@lancet.com

Please mention The Lancet as the source of this material

Issued by Tim Duffy, Acting North American Editorial and Press Coordinator, The Lancet
Press pressoffice@lancet.com Telephone: +44 (0)20 7424 4949/4249

A case-control study of more than 2000 people in India estimated the efficacy of mOPV1 to be 30% per dose against type 1 paralytic poliomyelitis in the Uttar Pradesh region, compared with 11% for the standard trivalent oral vaccine.

Between 76–82% of children aged 0–23 months in Uttar Pradesh were estimated to be protected by vaccination against type 1 poliovirus at the end of 2006 (after repeated rounds of vaccination with mOPV1)—compared with 59% at the end of 2004, prior to the introduction of mOPV1.

The authors conclude: "Achieving high coverage with the new vaccine in areas of persistent poliovirus transmission should substantially improve the probability of rapidly eliminating transmission of the disease."

In an accompanying Comment, Professor Paul Fine and Dr Ulla Griffiths, of the London School of Hygiene and Tropical Medicine, said: "The demonstration of superior effectiveness of mOPV1 vaccine adds to the evidence that termination of wild poliovirus transmission is technically feasible, given enough time, continued funding, political stability, and continued political support in the affected areas of the world."

Professor Kimberly M Thompson, Harvard School of Public Health, Boston, USA. T) +1 617 432 4285

Dr Bruce Aylward, Global Polio Eradication Initiative, World Health Organisation, Switzerland. T) +41 79 217 3438

Comment Professor Paul Fine, London School of Hygiene and Tropical Medicine, London, UK. T) +44 (0) 20 7927 2219






Page: 1 2 3

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
3. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
6. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
7. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
8. Framingham Study Shows Parents Who Live Long Pass On Lower Risk of Cardiovascular Disease
9. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
10. Tight Glycemic Control in the ICU
11. New Quality Control Systems for Every Laboratory Application
Post Your Comments:
(Date:5/21/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6csvbs/market_assessment ... "Market Assessment of Respiratory Diagnostics in the United ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service provides ... in the United States ... provides detailed analysis of the current and forecasted ...
(Date:5/21/2015)... REDWOOD CITY, Calif. , May 21, 2015  Cardica, ... 20, 2015, new employee Greg Watson , the company,s ... 400,000 shares of the company,s common stock, at a per ... May 20, 2015. The stock option was granted pursuant to ... board of directors in May 2015 under Rule 5653(c)(4) of ...
(Date:5/21/2015)... YORK , 21. Mai 2015 ... DPRX ), ein Unternehmen für ... auf die Entwicklung und Vermarktung von ... konzentriert, kündigte heute eine wissenschaftliche Posterpräsentation ... Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 und ...
Breaking Medicine Technology:United States and Europe Respiratory Diagnostics Market Assessment 2015 2Cardica Announces New Employment Inducement Grant 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... Direct Factor Xa Inhibitor,Shows a Significant Reduction ... with Enoxaparin with Similarly Low Bleeding,Rates , ... III clinical trial,data presented today at the ... Congress demonstrate that once-daily,rivaroxaban (Xarelto®) achieved superior ...
... Insmed Inc. (NASDAQ:INSM), a ,biopharmaceutical company focused on the ... metabolic diseases with unmet,medical needs, today announced that ... Emerging Growth,Opportunities Conference in New York City. ... Mandarin Oriental Hotel in New,York City, will run ...
Cached Medicine Technology:Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
(Date:5/22/2015)... 22, 2015 According to Berks and ... drug related death, totaling almost 2,500 confirmed drug deaths, as ... state officials, totals 2,489 deaths stemming from legal and illegal ... loses seven people every day to fatal overdoses or other ... out as one of the most rife with drug related ...
(Date:5/22/2015)... 22, 2015 Gateway Building Concepts is ... The services the company specialize in include decks, additions, ... pool houses and much more. , The redesigned ... owner of the company. It includes two geometrical lines ... was thought out to be used with many things ...
(Date:5/22/2015)... sweetFrog Enterprises, LLC. is pleased to announce the opening ... the 16th sweetFrog store located in the Lone Star State. ... the Inc. 500 list of fastest growing companies in 2014. ... Texas for 20 years and love the natural beauty and ... nearby Palestine, sweetFrog locations. “We are really excited about giving ...
(Date:5/22/2015)... Boca Raton, FL (PRWEB) May 22, 2015 ... organization which provides vascular, electrocardiogram (EKG), echocardiogram and ... of David Sempier, a highly respected All American National ... a multi-sport athlete, I find the high level of ... to both the athlete and their athletic trainers, this ...
(Date:5/22/2015)... Ticket Down is a reputable source for ... Eastern Conference Finals Tickets . All seating for the ... the ticket listing. , For the first time in ... of the Eastern Conference. One of the original franchises in ... and downs over the years, but the excitement level for ...
Breaking Medicine News(10 mins):Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3
... a Year, TAMPA, Fla., Sept. 18 In response ... a two-week coma with a craving for The,Melting Pot, the ... The Melting Pot will fly Jill Finley and her family ... at its annual,meeting. On May 26, Finley,s husband Ryan ...
... Sept. 18 The Raleigh based Sisko,Foundation is once ... tennis event with the third annual "Pick Up the ... outside the RBC Center.,NBC-17,s Kim Genardo will once again ... have the tennis event in the spring and the ...
... ... Hospital, MINNEAPOLIS, Sept. 18 ... released this year,s results from a,comprehensive hospital quality and safety survey of ... in,Rochester and Childrens, Hospitals and Clinics in Minneapolis and St. Paul,were named ...
... Discomfort Associated with Acute, ... Conditions such as Back Pain, SOMERSET, N.J., Sept. ... Drug Administration (FDA) has approved,SOMA(R) (carisoprodol) 250 mg as ... discomfort associated with acute, painful musculoskeletal,conditions, such as backache. ...
... STATION, N.J., Sept. 17 Merck & Co., Inc.,today ... reportedly filed by New,York State and New York City ... the suit as it has defended against the,Medicaid- related ... handful of other,states. Merck carefully studied VIOXX(R) before ...
... Medical practitioners, patients and employers recommend immediate,adoption ... Sept. 17 The Health IT Now!,Coalition, ... former Rep. Nancy,Johnson, held a Capitol Hill ... clear interoperable standards for the rapid deployment ...
Cached Medicine News:Health News:Update on Jill Finley Story, Coma Survivor 2Health News:Sisko Foundation Gears Up to 'Pick Up The Pace Against Breast Cancer' 2Health News:Four Minnesota Hospitals Rate High For Patient Safety and Quality 2Health News:FDA Approves SOMA(R) (carisoprodol) 250 mg 2Health News:FDA Approves SOMA(R) (carisoprodol) 250 mg 3Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 2Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 3Health News:Health IT Now! Coalition Urges Congress to Pass Health Information Technology Bill This Year 2Health News:Health IT Now! Coalition Urges Congress to Pass Health Information Technology Bill This Year 3
An injectable IOL, single-use injector for the IOL and post-op protective eye-shield all packaged in one handy, ready-to-use system pack....
... IOL is the newest advance in lens ... patient and surgeon in mind. Its unique ... crosslinked with PMMA haptics to provide superb ... performance and biocompatibility. The high memory lathe-cut ...
Raysoft Foldable Intraocular Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
Medicine Products: